ALPS Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

ALPS Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,590	Closed	-$339K	–	991
2021 Q3	$339K	Sell	7,590 -557	-7%	-$27.2K	﹤0.01%	803
2021 Q2	$444K	Sell	8,147 -3,004	-27%	-$178K	﹤0.01%	541
2021 Q1	$834K	Buy	11,151 +2,880	+35%	+$299K	0.01%	422
2020 Q4	$897K	Buy	8,271 +2,435	+42%	+$222K	0.01%	397
2020 Q3	$516K	Sell	5,836 -397	-6%	-$45.1K	0.01%	422
2020 Q2	$664K	Buy	+6,233	New	+$559K	0.01%	405
2019 Q2	–	Sell	-8,129	Closed	-$743K	–	902
2019 Q1	$743K	Buy	8,129 +352	+5%	+$24.5K	0.01%	397
2018 Q4	$433K	Buy	7,777 +1,822	+31%	+$138K	﹤0.01%	536
2018 Q3	$709K	Buy	5,955 +1,228	+26%	+$142K	﹤0.01%	470
2018 Q2	$483K	Buy	+4,727	New	+$585K	﹤0.01%	612

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ALPS Advisors's SYRS Position: Q4 2021 in Review

ALPS Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2021, closing a stake of 7,590 shares — an estimated $339K sold.

ALPS Advisors first reported a position in SYRS in Q2 2018 and held it in 10 quarters. The position peaked at $897K in Q4 2020. 90 funds tracked by Wall St. Rank hold SYRS as of Q4 2021.

ALPS Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
ALPS Advisors sold 7,590 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $339K.
ALPS Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 10 quarters.
ALPS Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $897K in Q4 2020.
90 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.